Internet for Pharmaceutical and Biotech Communities
| Newsletter | Post Jobs | Advertising |
 
 

 

  

Pharm/Biotech Resources

Outsourcing Guide

Cont. Education

Software/Reports

Training Courses

Web Seminars

Jobs

Buyer's Guide

Home Page

Pharm Patents /
Licensing

Pharm News

Federal Register

FDA Links

FDA Warning Letters

Pharm/Biotech Events

Consultants

Advertiser Info

Newsletter Subscription

Web Links

Suggestions

Site Map
 
 
   


Patent Classification

Treatment, T-Cells Related Disorders/Treatments

  1. Methods and pharmaceutical compositions for GnRH-I and GnRH-II modulation of T-cell activity, adhesion, migration and extravasation
     
  2. Modulation of T cell signaling threshold and T cell sensitivity to antigens
     
  3. Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
     
  4. Vaccine for activating helper function of CD8.sup.+ Tcells
     
  5. Co-stimulatory polypeptides
     
  6. Methods for producing target cell reactive lymphocytes
     
  7. Method of stimulating proliferation of regulatory T cells in a diabetic mammal
     
  8. Method for producing cytotoxic T-cells
     
  9. Methods for selectively enriching TH1 and TH2 cells
     
  10. DNA construct encoding CE7-specific chimeric T cell receptor
     
  11. Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
     
  12. Antigen transduced T cells used as a delivery system for antigens
     
  13. T-cell therapy formulation
     
  14. MHC class II antigen-presenting systems and methods for activating CD4.sup.+ T cells
     
  15. Methods and compositions for transforming dendritic cells and activating T cells
     
  16. Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
     
  17. CE7-specific chimeric T cell receptor
     
  18. Anti-human T-cell costimulating polypeptide monoclonal antibodies
     
  19. Methods and compositions for obtaining mature dendritic cells
     
  20. Detection of CD8+ T cell responses to M. tuberculosis
     
  21. JTT-1 protein and methods of inhibiting lymphocyte activation
     
  22. HIV-specific cytotoxic T-cell responses
     
  23. Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
     
  24. Antigen presenting mesenchymal stem cells
     
  25. Antibodies of the P2Y10 receptor useful in altering T lymphocyte function
     
  26. Methods for transfecting T cells
     
  27. Compositions and methods for dendritic cell-based immunotherapy
     
  28. B7-DC, Dendritic cell co-stimulatory molecules
     
  29. Methods and compositions for regulating T cell subsets by modulating transcription factor activity
     
  30. Simultaneous stimulation and concentration of cells
     
  31. Methods for treatment of HIV and other infections using a T cell or viral activator and anti-retroviral combination therapy
     
  32. Modulation of systemic memory T cell trafficking
     
  33. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
     
  34. Cloning and expression of HTLV-III DNA
     
  35. Immunotherapy using cytotoxic T lymphocytes (CTL)
     
  36. Simultaneous stimulation and concentration of cells
     
  37. P53-specific T cell receptor for adoptive immunotherapy
     
  38. Regulatory T cells; methods
     
  39. Modulation of .gamma..delta. T cells to regulate airway hyperresponsiveness
     
  40. Methods and compositions for transforming dendritic cells and activating T cells
     
  41. Combination immunogene therapy
     
  42. Vectors that repress heterologous promoter activity
     
  43. HCMV-reactive T cells and uses therefor
     
  44. Conjugates targeted to the interleukin-2 receptor
     
  45. Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
     
  46. Methods for modulating T cell responses by manipulating intracellular signal transduction
     
  47. Methods of detecting T-cell activation
     
  48. Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
     
  49. Killer T cell receptor recognizing human immunodeficiency virus
     
  50. Molecules designated B7L-1
     
  51. Induction of a Th1-like response in vitro
     
  52. Regulation of T cell-mediated immunity by tryptophan
     
  53. Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating T cells

Treatment, Tendon Related Disorders

  1. Method for treatment of tendinosis using platelet rich plasma
     
  2. Tendon-inducing compositions

Treatment, Thrombocytopenia

  1. Agents for preventing and treating thrombocytopenia
     
  2. Blood coagulation factor XIII for treating platelet disorders
     
  3. Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
     
  4. Anti-GPIIb/IIIa recombinant antibodies
     
  5. Method of treating heparin-induced thrombocytopenia
     
  6. Methods of treating thrombocytopenia
     
  7. Use of polypeptides for treating thrombocytopenia

Treatment, Thrombosis/Thrombotic Disorders

  1. Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses
     
  2. Solid dosage form of wetted heparin
     
  3. Antithrombotic therapy with antibodies binding to the A3 domain of von Willebrand factor (VWF)
     
  4. Glycine betaine and its use
     
  5. Heparin prodrugs and drug delivery stents formed therefrom
     
  6. Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
     
  7. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
     
  8. Non-neutralizing anti-aPC antibodies
     
  9. Methods of treating coagulapathic or thrombotic disorders
     
  10. Prodrugs of thrombin inhibitors
     
  11. Transdermal warfarin system
     
  12. Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
     
  13. Methods of treating thrombotic diseases with von Willebrand factor specific antibodies
     
  14. Assays for diagnosis of thrombophilic disease
     
  15. Antithrombin protein and DNA sequences from black fly
     
  16. Antithrombosis enzyme from the snake venom of agkistrodon acutus
     
  17. Methods for enhancing the lysis of coagulated blood with apolipoprotein E2 phenotype
     
  18. Methods for the treatment of thrombosis
     
  19. Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
     
  20. Stability for injection solutions
     
  21. Methods for the treatment of coagulation disorders with lipoprotein associated coagulation inhibitor (LACI)
     
  22. Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
     
  23. Pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
     
  24. Antithrombotic agents
     
  25. Monoclonal antibodies recognizing human platelet membrane glycoproteins and use thereof in anti-thrombotic therapy
     
  26. Antithrombin nucleotides and proteins from horn fly
     
  27. Highly purified mocarhagin, a cobra venom protease, polynucleotides encoding same and related proteases, and therapeutic uses thereof
     
  28. CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
     
  29. Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C
     
  30. Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
     
  31. Methods of treating thrombotic diseases with von Willebrand factor specific antibodies
     
  32. Antithrombotic materials and methods
     
  33. Microencapsulated plasminogen activators
     
  34. Production of agglomerates of inogatran and the compound inogatran anhydrate
     
  35. Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
     
  36. Antithrombosis enzyme from the snake venom of agkistrodon acutus
     
  37. Antithrobin nucleotides and proteins from horn fly
     
  38. Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation

Treatment, Tinnitus

  1. Topical application of muscarinic and opioid agents for treatment of tinnitus

Treatment, Tissue Factor Pathway Inhibitor

  1. Regulation of cytokine synthesis and release

Treatment, Tissue Repair/Engineering

  1. Self-assembling peptide amphiphiles for tissue engineering
     
  2. Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
     
  3. Method of preparing basement membrane, method of constructing basement membrane specimen, reconstituted artificial tissue using the basement membrane specimen and process for producing the same
     
  4. Multi-layer cell encapsulation for tissue engineering
     
  5. Use of neuropeptides for traumatic cartilage injury
     
  6. Method and material for enhanced tissue-biomaterial integration
     
  7. Tissue substitutes comprising stem cells and reduced ceria
     
  8. Transgene delivering retrovirus targeting collagen exposed at site of tissue injury
     
  9. Vascularization enhanced graft constructs
     
  10. Tissue engineered female reproductive organs
     
  11. Isolation and characterization of muscle regenerating cells
     
  12. Generating vascular smooth muscle cells in vitro from ES cells
     
  13. Vascularization enhanced graft constructs
     
  14. Aligned scaffolds for improved myocardial regeneration
     
  15. Cell scaffold matrices with incorporated therapeutic agents
     
  16. Biomaterial derived from vertebrate liver tissue
     
  17. In vivo synthesis of connective tissues
     
  18. Particulate acellular tissue matrix
     
  19. Tissue scaffold having aligned fibrils and artificial tissue comprising the same
     
  20. Injectable microspheres for tissue construction
     
  21. System and method for forming a cardiac muscle construct
     
  22. Decellularized bone marrow extracellular matrix
     
  23. Biological scaffolding material
     
  24. Conformable tissue repair implant capable of injection delivery
     
  25. Tissue glue with improved antiadhesive properties
     
  26. Implantable biodegradable devices for musculoskeletal repair or regeneration
     
  27. Composition and use of RAR antagonists for promoting chondrogenesis
     
  28. Enhanced submucosal tissue graft constructs
     
  29. Neutral self-setting calcium phosphate paste
     
  30. Supplemented and unsupplemented tissue sealants, methods of their production and use
     
  31. Transdermal thermal polymerization
     
  32. Supplemented and unsupplemented tissue sealants, methods of their production and use
     
  33. Drug releasing biodegradable fiber for delivery of therapeutics
     
  34. Plasma protein matrices and methods for their preparation
     
  35. Acellular biological material chemically treated with genipin
     
  36. Collagen/glycosaminoglycan matrix stable to sterilizing by electron beam radiation
     
  37. Decellularized tissue engineered constructs and tissues
     
  38. Collagen/polysaccharide bilayer matrix
     
  39. Particulate acellular tissue matrix
     
  40. Biological Bioadhesive composition and methods of preparation and use
     
  41. Synthetic compounds and compositions with enhanced cell binding
     
  42. Regenerated cellulose and oxidized cellulose membranes as potential biodegradable platforms for drug delivery and tissue engineering
     
  43. Reversibly cross-linked hydrogels
     
  44. Modifying tissue surfaces by liquid crystal formation
     
  45. Collagen/polysaccharide bilayer matrix
     
  46. Bioerodable polymeric adhesives for tissue repair
     
  47. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
     
  48. Tissue regenerative compositions for cardiac applications, method of making, and method of use thereof
     
  49. Protein-induced morphogenesis in liver tissue
     
  50. Fibrin microbeads prepared from fibrinogen, thrombin and factor XIII for binding cells
     
  51. Modifying tissue surfaces by liquid crystal formation
     
  52. Bioerodable polymeric adhesives for tissue repair

Treatment, Toxoplasmosis

  1. Toxoplasma gondii apical membrane antigen-1
     
  2. Toxoplasma gondii antigens
     
  3. Cloning of gene encoding the GP28.5 protein of Toxoplasma gondii; peptide fragments of said protein and their applications

  4. Mimotopic polypeptides of toxoplasma gondii and applications

Treatment, Transplantation/Implantation, Cell/Organ/Tissue

  1. Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
     
  2. Use of thymosin alpha 1 for the treatment of immunological diseases
     
  3. Method for storage and perfusion of organs using a solution comprising L-carnitine and isovaleryl L-carnitine
     
  4. Modulation of NKG2D for treating or preventing solid organ allograft rejection
     
  5. Protective solutions for organs
     
  6. Pre-transplant accommodated organs resistant to anti-donor immunity
     
  7. Method of determining that an organ is not suitable for transplantation and using it for testing substances
     
  8. Anti-interferon alpha antibodies
     
  9. Freeze-dried fibrin matrices and methods for preparation thereof
     
  10. Transplantation of human neural cells for treatment of neurodegenerative conditions
     
  11. Method for inducing selectively suppressed immune response to transplanted tissue or cells
     
  12. Treatment of bioprosthetic tissues to mitigate post implantation calcification
     
  13. Compositions and methods for the evaluation and resuscitation of cadaveric hearts for transplant
     
  14. Methods and compositions for the repair and/or regeneration of damaged myocardium
     
  15. Inhibition of antigen presentation with poorly catabolized polymers
     
  16. Method of stimulating stem cells
     
  17. Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation
     
  18. Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
     
  19. Method for monitoring the immune response and predicting clinical outcomes in transplant recipients
     
  20. Erythropoietin administration to improve graft survival
     
  21. Method for enhancing engraftment of cells using mesenchymal progenitor cells
     
  22. Stem cells and their use in transplantation
     
  23. Methods of screening for compounds that improve engraftment
     
  24. Cell lines
     
  25. Transgenic pigs carrying both hHO-1 and hDAF transgenes for xenotransplantation
     
  26. Oral tolerance induction by collagen to prevent allograft rejection
     
  27. Method for preserving organs for transplant
     
  28. Methods of using flt3-ligand in hematopoietic cell transplantation
     
  29. Solution for the preservation of hearts
     
  30. Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
     
  31. Method of evaluating myelosuppressive state
     
  32. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
     
  33. Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions
     
  34. Systems and methods for identifying organ transplant risk
     
  35. HA-1 antigen
     
  36. Materials and methods for management of hyperacute rejection in human xenotransplantation
     
  37. Implant device with a retinoid for improved biocompatibility
     
  38. Differentiation of adipose stromal cells into osteoblasts and uses thereof
     
  39. Enhanced submucosal tissue graft constructs
     
  40. Modified organs and cells for xenotransplantation
     
  41. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
     
  42. Method for predicting transplant rejection
     
  43. Hematopoietic cell composition for use in transplantation
     
  44. Method for remyelinating a demyelinized lesion due to injury in the brain or spinal cord
     
  45. Method of forming vascularized kidney tissue
     
  46. Composition and method for improving function of embryonic kidney transplants
     
  47. Transplants for myocardial scars
    48.  
  48. Method for growth of human conjunctival tissue equivalents for research, clinical ocular surface transplantation and tissue engineering
     
  49. Neural transplantation using pluripotent neuroepithelial cells
     
  50. Therapeutic delivery of carbon monoxide
     
  51. Composition and method for treating graft-versus-host disease
     
  52. Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
     
  53. Method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same
     
  54. Supercritical fluid extraction process for tissue preparation
     
  55. H-Y antigen
     
  56. Cold storage solution for organ and biological tissue preservation
     
  57. Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
     
  58. Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors
     
  59. Production of pancreatic islet cells and delivery of insulin
     
  60. Retinal cell grafts
     
  61. Use of interleukin-11 to prevent immune-mediated cytotoxicity
     
  62. Multi-layer cell encapsulation for tissue engineering
     
  63. Chemokine receptor antagonist and cyclosporin in combined therapy
     
  64. Measurement of protective genes in allograft rejection
     
  65. Composition comprising multipotent neural stem cells for generation of hematopoietic cells
     
  66. Three-dimensional ex vivo angiogenesis system
     
  67. Induction of beta cell differentiation in human cells by stimulation of the GLP-1 receptor
     
  68. Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
     
  69. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
     
  70. Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell
     
  71. Methods for enhancing graft survival by modulating heme oxygenase activity
     
  72. Method to determine an engrafting cell dose of hematopoietic stem cell transplant units
     
  73. Methods for inhibiting rejection of transplanted tissue
     
  74. Corneal storage fluid comprised of hyaluronic acid
     
  75. Methods for storing neural cells
     
  76. Agarose coated agarose beads containing cancer cells which produce cancer-cell proliferation-suppressing material
     
  77. Cell expansion system for use in neural transplantation
     
  78. Regulatory T cells; methods
     
  79. Methods for storing neural cells such that they are suitable for transplantation
     
  80. Porous biodegradable polymeric materials for cell transplantation
     
  81. Muscle cells and their use in cardiac repair
     
  82. Intraocular transplantation of encapsulated cells
     
  83. Peptide Compositions which induce immune tolerance and methods of use
     
  84. Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression
     
  85. Transgenic swine having HLA-D gene, swine cells thereof and xenografts therefrom
     
  86. Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
     
  87. Method of treating BK virus nephropathy
     
  88. Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
     
  89. Implantation of HSV-TK retrovirus producer cells to destroy glioma
     
  90. Use of nerve growth factor for the storage, culture or treatment of cornea
     
  91. Animal model for transplantation
     
  92. Compositions and methods for treating hyperimmune response in the eye
     
  93. Costimulatory blockade and mixed chimerism in transplantation
     
  94. Process for reducing mineralization of tissue used in transplantation
     
  95. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (LAG-3)
     
  96. Intraocular transplantation of encapsulated cells
     
  97. Membrane-bound C1 inhibitor
     
  98. Neural transplantation using proliferated multipotent neural stem cells and their progeny
     
  99. Attenuation of rejected cells transformed with adenovirus E3
     
  100. Mammalian myeloid progenitor cell subsets
     
  101. Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
     
  102. Transplantation of neural cells for the treatment of chronic pain or spasticity
     
  103. Non-myeloablative tolerogenic treatment
     
  104. Polysaccharide sponges for cell culture and transplantation
     
  105. Methods for inhibiting the rejection of a transplant organ in a subject with 5C8-specific antibodies

  106. Method of delivering oxygen to cells by electrolyzing water

  107. Modulation of multicellular aggregates by pressure from growth in a matrix

  108. Transplant encapsulation in a hydrogel matrix to obscure immune recognition

  109. Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans

  110. Prolonging survival of transplanted pancreatic cells 

  111. Methods and products for controlling the immune response of a mammal to glutamic acid decarboxylase
     
  112. Method of suppressing an immune response to a transplanted organ or tissue by administering an OX-2 protein
     
  113. Specific tolerance in transplantation
     
  114. Process for preparing novel ice-controlling molecules
     
  115. Induced tolerance to xenografts
     
  116. Methods for prevention and treatment of septic shock
     
  117. Therapeutic use for glycine
     
  118. Localized delivery of factors enhancing survival of transplanted cells
     
  119. Mechanically elongated neuronal cells
     
  120. Enhancement of transplant graft survival through nutritional immunomodulation with omega-9 fatty acid dietary supplement therapy
     
  121. Pharmaceutical preparation and method for treatment of diabetes
     
  122. Method for transplanting cells into the brain and therapeutic uses therefor

Treatment, Tuberculosis

  1. Tuberculosis vaccines comprising antigens expressed during the latent infection phase
     
  2. Compounds and methods for immunotherapy and diagnosis of tuberculosis
     
  3. Fusion proteins of mycobacterium tuberculosis
     
  4. Compounds and methods for immunotherapy and diagnosis of tuberculosis
     
  5. Fusion proteins of Mycobacterium tuberculosis
     
  6. Tuberculosis antigen detection assays and vaccines
     
  7. Fusion proteins of Mycobacterium tuberculosis
     
  8. Method for the treatment or prophylaxis of tuberculosis
     
  9. Tuberculosis vaccines including recombinant BCG strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase
     
  10. Secreted proteins of Mycobacterium tuberculosis and their use as vaccines and diagnostic reagents
     
  11. High resolution typing system for pathogenic Mycobacterium tuberculosum
     
  12. Targeting of triacylglycerol synthase gene for tuberculosis treatment
     
  13. Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
     
  14. Reduction in the virulence of Mycobacterium tuberculosis and protection against tuberculosis by means of phoP gene inactivation
     
  15. Methods, kits and assay system for detecting drug-resistant Mycobacterium tuberculosis
     
  16. Herbal extracts of Salicornia species, process of preparation thereof, use thereof against tuberculosis
     
  17. Synthetic peptide, inhibitor to DNA viruses
     
  18. Compounds and methods for immunotherapy and diagnosis of tuberculosis
     
  19. Detection of CD8+ T cell responses to M. tuberculosis
     
  20. Mycobacterial proteins, microorganisms producing them and their use for vaccines and the detection of tuberculosis
     
  21. Compounds and methods for diagnosis and immunotherapy of tuberculosis
     
  22. Fusion proteins of mycobacterium tuberculosis antigens and their uses
     
  23. High resolution typing system for pathogenic Mycobaterium tuberculosum
     
  24. Mycobacterium tuberculosis immunizationg
     
  25. Inclusion complex of Rifampicin, an anti-tubercular drug, with β-cyclodextrin or 2-hydroxypropyl β-cyclodextrin and a process thereof
     
  26. TB diagnostic based on antigens from M. tuberculosis
     
  27. Compounds and methods for immunotherapy and diagnosis of tuberculosis
     
  28. Compounds and methods for diagnosis of tuberculosis
     
  29. Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutinin
     
  30. Process for the preparation of a vaccine for the treatment of tuberculosis and other intracellular infections diseases and the vaccine produced by the process
     
  31. Tuberculosis vaccine
     
  32. Molecular differences between species of the M. tuberculosis complex
     
  33. Tuberculosis vaccine
     
  34. Reporter gene based method for the screening of anti-tuberculosis drugs by using essential and regulatory genes of mycobacteria as drug target
     
  35. Compounds and methods for immunotherapy and diagnosis of tuberculosis
     
  36. Compounds for diagnosis of tuberculosis and methods for their use
     
  37. Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
     
  38. Compounds and methods for diagnosis of tuberculosis
     
  39. Genes encoding mycobacterial proteins associated with cell binding and cell entry and uses thereof
     
  40. Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated

  41. DNA molecule encoding for cellular uptake of mycobacterium tuberculosis and uses thereof

  42. Polynucleotide tuberculosis vaccine

  43. Mycrobacterial proteins, microorganisms producing same and uses of said proteins in vaccines and for detecting tuberculosis

Treatment, Typhoid

  1. Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine

Treatment, Ulcer, Intraoral

  1. Lesion and ulcer medication

Treatment, Ulcer, Peptic/Other Related Disorders

  1. Methods for treating ulcers and gastroesophageal reflux disease
     
  2. Therapeutic and diagnostic methods for ulcerative colitis and associated disorders
     
  3. Anti-ulcer pharmaceutical composition and the preparation thereof
     
  4. Method for treating gastric disorders using optically pure (-) pantoprazole
     
  5. Liquid pharmaceutical composition
     
  6. Immunogenic compositions against gastrin peptides
     
  7. Glycoprotein having inhibitory activity against helicobacter pylori colonization
     
  8. Therapeutic and diagnostic methods for ulcerative colitis and associated disorders
     
  9. Pharmaceutical composition useful in the treatment of peptic ulcers
     
  10. Substituted benzimidazole dosage forms and method of using same
     
  11. Method of treating gastric ulcer by administration of epidermal growth factor
     
  12. Strain of Lactobacillus gasseri

Treatment, Ulcer, Pressure

  1. Methods of treating cutaneous ulcers and grafts using IL-23
     
  2. Nutritional composition for the treatment of pressure ulcers

Treatment, Urological Related Disorders

  1. Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction
     
  2. Medicament for preventive and/or therapeutic treatment of lower urinary tract symptom
     
  3. Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
     
  4. Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
     
  5. Use of extracts of the genus Cimicifugaas organoselective medicines for treating diseases of the genitourinary system caused by sex hormones
     
  6. Interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis
     
  7. Implantable particles for the treatment of gastroesophageal reflux disease
     
  8. Recombinant DNA, plasmid, transformed microorganism and vaccine protein for prevention and therapy of urinary tract infection
     
  9. Uro-genital condition treatment system
     
  10. Synthetic peptide composition as immunogens for prevention of urinary tract infection
     
  11. Use of neurotoxin therapy for treatment of urologic and related disorders

Treatment, Vaginitis/Vaginal Care/Related Disorders

  1. Vaginal treatment composition containing xylitol
     
  2. Low concentration of peroxide for treating or preventing vaginal infections
     
  3. Vaginal pharmaceutical compositions and methods for preparing them
     
  4. Medicated tampon
     
  5. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
     
  6. Lactic acid producing bacteria for use as probiotic organisms in the human vagina
     
  7. Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method
     
  8. Surfactant prevention of vaginitis and lung complications from cancer chemotherapy
     
  9. Warming and nonirritating lubricant compositions and method of comparing irritation
     
  10. Composition for synthetic cervical mucus formulation
     
  11. Intravaginal drug delivery devices for the administration of an antimicrobial agent
     
  12. Composition and method for treatment of vaginal dryness
     
  13. Treatment of vulvovaginitis with spirostanol enriched extract from Tribulus terrestris
     
  14. Uro-genital condition treatment system
     
  15. Inhibition of exoprotein production from gram positive bacteria
     
  16. Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof

Treatment, Veterinary Medicine

  1. DNA sequences, vectors and proteins of avian influenza hemagglutinin
     
  2. Barrier film-forming germicidal composition for controlling mastitis
     
  3. N-linked glycosylation alteration in E1 glycoprotein of classical swine fever virus and novel classical swine fever virus vaccine
     
  4. Proteins derived from white spot syndrome virus and uses thereof
     
  5. Therapeutic method of treating brain trauma in rodents with VCP
     
  6. DNA vaccine against North American spring viremia of carp virus
     
  7. Canine RANKL and methods for preparing and using the same
     
  8. Systems for genome selection
     
  9. Bacteriocins and novel bacterial strains
     
  10. Encapsulated vaccines for the oral vaccination and boostering of fish and other animals
     
  11. Nucleic acids encoding recombinant 56 and 82 kDa antigens from gametocytes of Eimeria maxima and their uses
     
  12. Hybridoma producing antibodies to Lawsonia intracellularis
     
  13. Modified leukotoxin gene and protein
     
  14. Active compound-containing solid moulded bodies for external use against parasites on animals
     
  15. Compositions for eliciting an immune response against Mycobacterium avium subspecies paratuberculosis
     
  16. Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
     
  17. Sequences diagnostic for foot and mouth disease
     
  18. Growth stimulant compositions
     
  19. CpG DNA adjuvant in avian vaccines
     
  20. Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus and uses thereof
     
  21. Hsp70 from Arthrobacter
     
  22. Method and composition for the control of gastrointestinal parasites in animals
     
  23. Campylobacter glycans and glycopeptides
     
  24. Antibiotic alternatives
     
  25. Methods for determining effects of maternal treatments on offspring
     
  26. Needle-free administration of FeLV vaccines
     
  27. Vaccine against Yersinia comprising one or two antibodies, one specific for Yersinia pestis F1-antigen and the other one for Yersinia pestis V-antigen 
     
  28. Vaccine comprising an attenuated pestivirus
     
  29. Promoter gene, recombinant turkey herpesvirus having the novel promoter gene, and poultry vaccine including the recombinant herpes virus of turkey
     
  30. Bacterial phytases and method for producing same
     
  31. Fatty acid antimicrobial
     
  32. Vaccine against foot-and-mouth disease
     
  33. Kennel cough vaccine
     
  34. Vaccine to control equine protozoal myeloencephalitis in horses
     
  35. Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
     
  36. Recombinant infectious laryngotracheitis virus and uses thereof
     
  37. In Ovo vaccine against infectious bursal disease
     
  38. Lawsonia intracellularis vaccine
     
  39. Artificial chromosomes comprising EHV sequences
     
  40. Method for treatment of laminitis in animals
     
  41. Population of Hoxb8 mutants and uses in identifying agents for treating repetitive behaviors
     
  42. Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor
     
  43. Nucleic acids encoding recombinant 56 and 82 kDa antigens from gametocytes of Eimeria maxima and their uses
     
  44. Cold-adapted equine influenza viruses
     
  45. Canine IL-13 immunoregulatory proteins and uses thereof
     
  46. Reovirus for the treatment of cellular proliferative disorders
     
  47. Protein sequences containing antigenized antibodies for foot-and-mouth disease
     
  48. Bioactive peptides, uses thereof and process for the production of same
     
  49. Coccidial vaccine and methods of making and using same
     
  50. In vivo method for producing female offsprings in bovines
     
  51. Methods and vaccines for providing in ovo protection against turkey rhinotracheitis
     
  52. Taste masked veterinary formulation
     
  53. Circovirus sequences associated with piglet weight loss disease (PWD)
     
  54. Immunization of fish with plant-expressed recombinant proteins
     
  55. Polypeptides containing polymorphisms of the repeated regions of pertactin in Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica, their use in diagnostics, and in immunogenic compositions
     
  56. Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies
     
  57. Methods for identification of alport syndrome
     
  58. Method for treating bacterial infections in horses or pigs with tilmicosin
     
  59. Intratesticular injection of chemical sterilant
     
  60. Method of identifying high immune response animals
     
  61. Immunization of dairy cattle with chimeric GapC protein against Streptococcus infection
     
  62. Selecting animals for parentally imprinted traits
     
  63. Vaccines containing ribavirin and methods of use thereof
     
  64. DNA vaccine expressing HA1 of equine-2 influenza virus
     
  65. Topical compositions for veterinary uses
     
  66. Coccidiosis poultry vaccine
     
  67. Equine Fc epsilon receptor alpha protein
     
  68. VP1 of foot-and-mouth disease virus
     
  69. Marek's disease virus vaccine
     
  70. Ovo immunization against infectious bronchitis
     
  71. IL4 receptor antagonists for horse, dog and cat
     
  72. Process for the synchronization of ovulation for timed breeding without heat detection
     
  73. Streptococcus agalactiae vaccine
     
  74. Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines
     
  75. Compositions and methods for enhancing disease resistance in fish
     
  76. Vaccine against ISA virus
     
  77. Beneficial effect of distiller's grain in cardiovascular disease
     
  78. Circovirus sequences associated with piglet weight loss disease (PWD)
     
  79. Methods of detecting early renal disease in animals
     
  80. Method of enhancing reproductive performance in sows
     
  81. Escherichia coli strain for an oral vaccine against post-weaning diarrhea in pigs
     
  82. Coccidiosis vaccines
     
  83. Method for treating roundworm infestations in animals
     
  84. Method for supplying bioavailable methionine to a cow
     
  85. Infectious bovine viral diarrhea virus clone
     
  86. Method and product for treating cancer in pets
     
  87. Bovine growth hormone recombinantly produced in E. coli
     
  88. Method of treating livestock footbath solutions
     
  89. Genetic test for the identification of carriers of complex vertebral malformations in cattle
     
  90. Compositions and methods for detection of Ehrlichia canis and Ehrlichia chaffeensis antibodies
     
  91. Antigens for immunocontraception
     
  92. Recombinant infectious laryngotracheitis virus and uses thereof
     
  93. Canine herpes virus alpha transinducing factor nucleic acid molecules
     
  94. Method and apparatus for detecting conception in animals
     
  95. Mycoplasma hyopneumoniae bacterin vaccine
     
  96. In ovo vaccination against coccidiosis
     
  97. Vaccine for the prevention of bacterial infection of the bovine mammary gland
     
  98. Lawsonia intracellularis proteins, and related methods and materials
     
  99. Method for the detection of prion diseases
     
  100. Production of an immunovariant strain of Eimeria maxima contributes to strain cross-protection with other Eimeria maximas
     
  101. Antigenic class of avian reoviruses
     
  102. Direct-fed microbial
     
  103. Diagnosis of spongiform diseases
     
  104. Use of a polypeptide for treatment of pruritis in animals
     
  105. Ectoparasiticidal aqueous suspension formulations of spinosyns
     
  106. Antithrombin nucleotides and proteins from horn fly
     
  107. Lawsonia intracellularis vaccine
     
  108. Duck pneumovirus and corresponding vaccines
     
  109. Feline calicivirus genes and vaccines in particular recombinant vaccines
     
  110. Treating arthritis in animals with dietary supplements
     
  111. Coccidial vaccine and methods of making and using same
     
  112. Effervescent solid composition of matter
     
  113. Method for improving the quality of sperm for artificial insemination of animals
     
  114. Monoclonal antibodies to Sarcocystis neurona and uses therefor
     
  115. Compositions and methods for early pregnancy diagnosis
     
  116. One dose vaccination with Mycoplasma hyopneumoniae
     
  117. Process for improving glucose and insulin metabolism in pet animals with a food composition
     
  118. Process for improving glucose metabolism, satiety, and nutrient absorption in companion animals
     
  119. Polynucleotide vaccine formula in particular against bovine respiratory pathology
     
  120. Over-expressing homologous antigen vaccine and a method of making the same
     
  121. Detection of sarcocystis neurona
     
  122. Melanocortin-4 receptor gene and use as a genetic marker for fat content, weight gain, and/or feed consumption of animals
     
  123. Strain of the western equine encephalitis virus
     
  124. Recombinant scFV antibodies specific to Eimeria spp. responsible for coccidiosis
     
  125. Antibodies for judging possibility of the onset of bovine leukemia
     
  126. Method to treat laminitis and reduce dietary intake for horses
     
  127. Peptide, immunogenic composition and vaccine or medical preparation, a method to immunize animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine
     
  128. Antimicrobial peptides isolated from fish
     
  129. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals
     
  130. Method of vaccination of newly hatched poultry
     
  131. 41 kDa Cryptosporidium parvum oocyst wall protein
     
  132. Fatty acid antimicrobial
     
  133. Cold-adapted equine influenza viruses
     
  134. Ovo delivery of an immunogen containing implant
     
  135. Compositions of parasitic helminth PLA2 nucleic acid molecules and uses thereof
     
  136. Method of modulating fertility in animals by IL-11
     
  137. Bovine footrot treatment and prevention
     
  138. Assay for propensity for canine malignant hyperthermia
     
  139. Broad spectrum antimicrobial compound and treatment
     
  140. Compositions and methods for reducing the amount of salmonella in livestock
     
  141. Injectable anthelmintic compositions and methods for using same
     
  142. Variant tax gene of bovine leukemia virus
     
  143. Methods and compositions for prevention and treatment of Clostridium difficile-associated diseases
     
  144. Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
     
  145. Swine vesicular disease virus expression vectors
     
  146. Prediction of growth performance and composition in animals, including cattle, from response to growth hormone releasing hormone
     
  147. Avian pneumovirus vaccine
     
  148. Lawsonia intracellularis proteins, and related methods and materials
     
  149. Process for purifying human papillomavirus virus-like particles
     
  150. Methods for detecting and reversing resistance to macrocyclic lactone compounds
     
  151. Antimicrobial composition useful for the treatment of bovine mastitis
     
  152. Treating feline-specific disorders by orally administering Hydrastis canadensis
     
  153. Temperature sensitive plasmids of P. haemolytica
     
  154. Feline cytokine protein
     
  155. Method for treatment and prevention of mastitis
     
  156. Vaccines for the protection of cattle from psoroptic scabies
     
  157. Diagnostic agent and method to determine pregnancy in ruminants
     
  158. Equine infectious anemia challenge model for testing vaccines, diagnostics and treatments
     
  159. Veterinary vaccines
     
  160. Chimeric gene formed of the DNA sequences that encode the antigenic determinants of four proteins of L. infantum, useful of serologic diagnosis of canine leishmaniosis and protein obtained
     
  161. Diagnosing an animal for pyrophosphate gout, osteoporosis, or osteoarthritis by assaying intracellular pyrophosphate content in peripheral blood cells
     
  162. Feline cytokine protein
     
  163. Method of alleviating the violence and stimulating the appetite of stag in the puberty age of the fall and method of promoting the growth of stag's horn
     
  164. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
     
  165. Genetically engineered cell culture adapted infectious bursal disease virus (IBDV) mutants
     
  166. Gene treatment to enhance feed efficiency and growth rate of livestock
     
  167. Cold-adapted equine influenza viruses
     
  168. Live vaccine constituting minor risk for humans
     
  169. Processes for preparation of Marek's Disease using continuous mammalian cell lines
     
  170. Nucleic acid vaccination for parvoviral infections
     
  171. Delivery of nucleic acid into aquatic animals
     
  172. Method for promoting ovulation, parturition, and lactation in mammals
     
  173. Antithrobin nucleotides and proteins from horn fly
     
  174. Intra-vaginal device for pigs
     
  175. Live vaccine against Brucellosis
     
  176. Immortal cell line derived from grouper Epinephelus coioides and its application therein
     
  177. Method for reducing body weight
     
  178. Method of increasing the production and improving the quality of semen

  179. In ovo vaccination of marek's disease type I virus

  180. Gene transfer in chickens by introduction of DNA into muscle in ovo

  181. Bactericide against vancomycin resistant enterococcus

  182. Method for treatment of canine distemper

  183. Method of treatment using papillomavirus L2 protein

  184. Polynucleotide vaccine formula in particular against bovine respiratory pathology

  185. Method for supplying bioavailable methionine to a cow

  186. Control of microbial populations in the gastrointestinal tract of animals 

  187. System for prophylactic treatment of mammary disorders
     
  188. Use of bicozamycin for the manufacture of a medicament for treating infections with enterohemorrhagic e. coli
     
  189. Process for decreasing adiposity using vitamin a as a dietary supplement
     
  190. Live attenuated Venezuelan Equine encephalitis vaccine
     
  191. Topical nitric oxide donor compositions

Treatment, Vigilance Disorders

  1. Method for correcting the vigilance disorders associated with myopathies

Treatment, Viral Infection

  1. Detection of mutations in a gene associated with resistance to viral infection, OAS1
     
  2. Kits for diagnosis and monitoring of viral infection by analysis of viral transrenal nucleic acids in urine
     
  3. Human cytomegalovirus neutralising antibodies and use thereof
     
  4. Medicinal compositions for preventing or treating viral myocarditis
     
  5. Methods for treatment of severe acute respiratory syndrome (SARS)
     
  6. Compositions and methods for detecting a non plus-stranded RNA virus
     
  7. Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
     
  8. Anti-viral activity of cathelicidin peptides
     
  9. Methods and reagents for diagnosing hantavirus infection
     
  10. Compositions and methods for treating intracellular diseases
     
  11. Methods of treating and preventing neurological symptoms caused by avian reovirus and novel associated characteristics
     
  12. Cellular targets for treatment of retroviral infection
     
  13. Use of milk serum apoproteins in the treatment of microbial or viral infection
     
  14. Kahalalide compositions
     
  15. Liposomes coated with selected antibodies that bind to aminophospholipids
     
  16. Compositions of coronaviruses with a recombination-resistant genome
     
  17. Assay to detect viral uncoating
     
  18. Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
     
  19. Production of "biological carriers" for induction of immune responses and inhibition of viral replication
     
  20. Combined cancer treatment methods using selected antibodies to aminophospholipids
     
  21. Anti-virus therapy for respiratory diseases
     
  22. Methods of treating viral infection with IL-10 receptor antagonists
     
  23. Methods of treating or preventing a disease, disorder or condition associated with a viral infection
     
  24. Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
     
  25. Preventing bacterial or viral infectivity and composition containing infection preventing additive
     
  26. Method of generating and/or increasing an immune response against RSV
     
  27. Homogeneous preparations of IL-28 and IL-29
     
  28. Nucleic acids encoding a novel influenza virus non-structural protein (NS1)-binding host factor designated NS1I-1
     
  29. Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof
     
  30. Homogeneous preparations of IL-28A cysteine mutants
     
  31. Homogeneous preparations of IL-28A mutants
     
  32. Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
     
  33. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
     
  34. Treatment of diseases caused by viral infection
     
  35. Method of making modified immunodeficiency virus particles
     
  36. Transgenic bovines having reduced prion protein production
     
  37. Assays and therapies for latent viral infection
     
  38. Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
     
  39. Recombinant DNA constructs for GAG polypeptides and polypeptides produced thereby
     
  40. Identification of viral agents in breast ducts and antiviral therapy therefore
     
  41. Compositions and methods for immunotherapy of cancer and infectious diseases
     
  42. Prion protein dimers useful for vaccination
     
  43. Predictive assay for immune response
     
  44. Amended recombinant cells for the production and delivery of gamma interferon as an antiviral agent, adjuvant and vaccine accelerant
     
  45. Method for treating a viral infection related or a chemical toxin related hepatic injury with deltorphin D
     
  46. Induction of immunity using inhibitors of granzymes
     
  47. Compositions and methods for eliciting immune or anti-infective responses
     
  48. GB virus C and methods of treating viral infections
     
  49. Inhibition of cellular proteases
     
  50. Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs
     
  51. Methods for treating viral infection using IL-28 and IL-29
     
  52. Identification of viral agents in breast ducts and antiviral therapy therefore
     
  53. Technology of intracellular delivery of DNA oligonucleotides to improve drug activity
     
  54. Method of treatment using interferon-tau
     
  55. Antiviral substances from plant cuticular and epicuticular material
     
  56. Assays and therapies for latent viral infection
     
  57. Method and composition for the treatment of a viral infection
     
  58. Antiviral substances from plant cuticular and epiciticular material
     
  59. Method of inhibiting formation of Neisseria gonorrhea and Neisseria meningiditis
     
  60. Inactivation of viral infections agents by chemiluminescence activated light-sensitive compounds
     
  61. B7-DC, Dendritic cell co-stimulatory molecules
     
  62. Antiviral composition comprising glycine amide
     
  63. Utilization of interferon alpha 5 in the treatment of viral hepatopathies
     
  64. Combating side-effects
     
  65. Therapeutic compositions and methods for treating viral infection
     
  66. Methods related to immunostimulatory nucleic acid-induced interferon
     
  67. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
     
  68. Methods and reagents to detect and characterize norwalk and related viruses
     
  69. Preparation of a therapeutic composition
     
  70. Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases
     
  71. Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection
     
  72. Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
     
  73. Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
     
  74. Inhibition of retrovirus infection
     
  75. Process for making antifusogenic fusion peptides that form inclusion bodies
     
  76. Reagent for detecting and monitoring viral infections
     
  77. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
     
  78. Method and composition for treating viral outbreaks
     
  79. Method and kit for detecting resistance to antiviral drugs
     
  80. Isolated peptide or polypeptide of the extracellular portion of the human interferon receptor (IFN-R)
     
  81. Attenuated microorganisms for the treatment of infection
     
  82. Methods of using cyanovirins to inhibit viral infection
     
  83. Treatment of viral infections
     
  84. Vectors that repress heterologous promoter activity
     
  85. Treatment of dermal tumors, warts, and viral infections of the respiratory tract in humans using heat-killed P. acnes
     
  86. EIAV p26 deletion vaccine and diagnostic
     
  87. HCMV-reactive T cells and uses therefor
     
  88. Retrocyclins: antiviral and antimicrobial peptides
     
  89. Type-1 ribosome-inactivating protein
     
  90. Compositions and methods for the treatment of viral disorders
     
  91. Method for treating papillomavirus infections
     
  92. Method for selective inactivation of viral replication
     
  93. Method for selective inactivation of viral replication
     
  94. Prophylactic and therapeutic monoclonal antibodies
     
  95. Peptide fragment of respiratory syncytial virus protein G, immunogenic agent, pharmaceutical composition containing it and preparation method
     
  96. Elevation of circulating blood histamine levels
     
  97. Method of treating BK virus nephropathy
     
  98. Conjugates of antiviral proteins or peptides and virus or viral envelope glycoproteins
     
  99. Inhibition of viral infection using antigen-binding proteins
     
  100. Anti viral composition
     
  101. Binding moieties for human parvovirus B19
     
  102. Pharmaceutical composition of the intercellular adhesion molecule ICAM-1 for use in anti-viral prophylactic therapy
     
  103. Methods of using cyanovirins topically to inhibit viral infection
     
  104. Method and composition for topical treatment of viral lesions

  105. Target therapies for treating common viral infections

  106. Method of allophycocyanin inhibition of enterovirus and influenza virus reproduction resulting in cytopathic effect

  107. Methods and compositions for inhibition of viral replication
     
  108. Chimeric viral proteins
     
  109. Peptides that block viral infectivity and methods of use thereof

Treatment, Weight Control/Gain/Obesity

  1. Dietary supplements containing extracts of aronia and methods of using same to promote weight loss
     
  2. Agent for inhibiting visceral fat accumulation
     
  3. Methods of reducing visceral fat by increasing levels of insulin-like growth factor-I (IGF-I)
     
  4. Method of assaying satiety enhancing tastants
     
  5. Compositions and methods for modulation of KSR1 and KSR2 interactions
     
  6. Methods and related compositions using specific indanes to reduce weight and inhibit lipase, .alpha.-amylase and .alpha.-glucosidase activity in mammals
     
  7. Human chorionic gonadotropin (hCG) formulations for facilitating weight loss and body contouring
     
  8. Method for controlling body weight in estrogen-insufficient women
     
  9. Melanocortin receptor templates, peptides and use thereof
     
  10. Methods and compositions for modulating adipocyte function
     
  11. Viral obesity methods and compositions
     
  12. Comprehensive pharmacologic therapy for treatment of a dysfunction
     
  13. Compounds for use in weight loss and appetite suppression in humans
     
  14. Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
     
  15. Compounds for use in weight loss and appetite suppression in humans
     
  16. Method of evaluating compound efficacious in treating obesity
     
  17. GDF3 propeptides and related methods
     
  18. Homotrimeric extended OBG3 globular head and uses thereof
     
  19. Compositions and methods of use of targeting peptides against placenta and adipose tissues
     
  20. Inhibition of olfactory neurosensory function to treat eating disorders and obesity
     
  21. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
     
  22. Tocopherol and tocotrienol anti-obesity medicaments
     
  23. Agonists and antagonists of prolixin for the treatment of metabolic disorders
     
  24. Decreased fat absorption with an anti-lipase antibody
     
  25. Viral obesity methods and compositions
     
  26. Comprehensive pharmacologic therapy for treatment of obesity including cysteine
     
  27. Delivery system for appetite suppressant
     
  28. Methods of increasing lean tissue mass using OB protein compositions
     
  29. Antiobestic agents and health foods
     
  30. Peptide having appetite stimulating activity
     
  31. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
     
  32. Anti-obestic composition
     
  33. Compositions and methods for treating obesity
     
  34. Preparation and administration of jojoba product for reducing weight, fat and blood lipid levels
     
  35. Inhibition of olfactory neurosensory function to treat eating disorders and obesity
     
  36. Oral compositions for the treatment of non-diabetic obese mammals, including humans
     
  37. Method for treating obesity
     
  38. Product and method for control of obesity
     
  39. Compositions and methods for body weight loss
     
  40. Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
     
  41. Bioavailable composition of natural and synthetic HCA
     
  42. Compositions and methods for body weight management
     
  43. Plant derived or derivable material with appetite suppressing activity
     
  44. Obesity gene
     
  45. Exendins, exendin agonists, and methods for their use
     
  46. Method for reducing food intake
     
  47. OBG3 globular head and uses thereof for decreasing body mass
     
  48. Adiponectin gene therapy
     
  49. Use of exendins for the reduction of food intake
     
  50. Target for treating athersclerosis, obesity and type II diabetes
     
  51. Transgenic non-human animals expressing a truncated activintype II receptor
     
  52. Chewing gum containing calcium
     
  53. Compounds for altering food intake in humans
     
  54. Method for treating obesity and for inhibiting adipocyte activity
     
  55. Herbal compositions and methods for diabetes and weight loss management
     
  56. Methods, pharmaceutical and therapeutic compostions for administering adenosine
     
  57. Animal model
     
  58. Chemical composition for aiding the absorption, binding and elimination of undigested fat
     
  59. Methods of treating obesity using a neurotensin receptor ligand
     
  60. Methods for promoting weight gain using GPE-related compounds
     
  61. Human gene relating to respiratory diseases and obesity
     
  62. Regulators of PPAR.delta. (.beta.) and their use in the treatment of obesity and insulin resistance
     
  63. Viral obesity methods and compositions
     
  64. Chewing gum with liquid medium
     
  65. Gene therapy for obesity
     
  66. OB protein-polymer chimeras
     
  67. Appetite suppressant toothpaste
     
  68. Comprehensive pharmacologic therapy for treatment of obesity
     
  69. Methods for suppressing appetite and enhancing exercise and recovery
     
  70. Adrenergically-mediated weight loss product
     
  71. Composition for growth hormone production and release, appetite suppression, and methods related thereto
     
  72. Chimeric proteins comprising the extracellular domain of murine Ob receptor
     
  73. Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery
     
  74. Satiety inducing composition comprising Neuropeptide Y analogues and methods of inducing satiety and treating a disease or condition associated with it
     
  75. Weight loss product
     
  76. Ob receptor and methods for the diagnosis and treatment of body weight disorders

  77. Materials and methods for the treatment or prevention of obesity

  78. Methods for inducing weight loss in a human with materials derived from Citrus varieties
     
  79. Methods for increasing the muscle mass of a human with materials derived from citrus varieties
     
  80. Azaftig, a proteoglycan for monitoring cachexia and for control of obesity
     
  81. Weight loss induced by alpha interferon and gamma interferon
     
  82. Regulation of appetite, body weight and athletic function with materials derived from citrus varieties

Treatment, West Nile and Related Disorders

  1. Vaccines against Japanese encephalitis virus and West Nile virus
     
  2. Screening for West Nile Virus antiviral therapy
     
  3. Detection of West Nile virus infection and vaccination
     
  4. Screening for West Nile Virus antiviral therapy 
     
  5. Infectious DNA as a vaccine against west nile and other flaviviruses
     
  6. Methods for preventing or ameliorating West Nile encephalitis
     
  7. Vaccines against West Nile Virus
     
  8. Nucleic acid vaccines for prevention of flavivirus infection
     
  9. Methods of treating West Nile virus infection

Treatment, Wound/Scar Healing

  1. Apparatus and method for detecting bacterial growth beneath a wound dressing
     
  2. Method for accelerated wound healing using novel fibrous webbings
     
  3. Hemostatic media
     
  4. Method of treating a wound utilizing suction
     
  5. Compositions and processes for accelerated wound healing using novel fibrous webbings
     
  6. Wound healing dressing for enhancing fibrocyte formation
     
  7. Method for treating wound, dressing for use therewith and apparatus and system for fabricating dressing
     
  8. Antibodies to heparin-binding growth factor (HBGF) polypeptides
     
  9. Nutraceutical treatments for diabetic and non-diabetic wound healing
     
  10. Wound dressing, ingredient delivery device and IV hold-down, and method relating to same
     
  11. Method for preventing the formation of adhesions following surgery or injury
     
  12. Wound dressings, apparatus, and methods for controlling severe, life-threatening bleeding
     
  13. Wound dressings with anti-microbial and zinc-containing agents
     
  14. Polyurethane foam dressing with improved moisturization
     
  15. Wound treatment device
     
  16. Wound dressing
     
  17. Controlled release therapeutic wound dressings
     
  18. Methods and compositions for topical wound treatment
     
  19. Methods and compositions for tissue regeneration
     
  20. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
     
  21. Protective factors against inflammation, burns and noxious stimuli
     
  22. Method for stimulating wound healing
     
  23. Wound healing and treatment of fibrosis
     
  24. HoxD3, HoxA3 and HoxB3 compositions and methods for improved wound healing
     
  25. Method and composition for treating skin wounds with epidermal growth factor
     
  26. Growth factor complex
     
  27. Wound and cutaneous injury healing with a nucleic acid encoding perlecan
     
  28. Dressing for treatment of short wounds located in high tension areas
     
  29. Compositions and methods for wound healing
     
  30. Use of the cathelicidin LL-37 and derivatives thereof for wound healing
     
  31. Carrier with solid fibrinogen and solid thrombin
     
  32. Agents for wound healing
     
  33. Pain-sensitive therapeutic wound dressings
     
  34. Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same
     
  35. Method of delivering therapeutic agents to site of tissue injury
     
  36. Povidone-containing carriers for polypeptide growth factors
     
  37. Methods of treating wounds using IL-23
     
  38. Decellularized bone marrow extracellular matrix
     
  39. Device and methods for sequential, regional delivery of multiple cytotoxic agents and directed assembly of wound repair tissues
     
  40. Methods and compositions for healing and repair of articular cartilage
     
  41. Method for treating wounds to promote healing
     
  42. Protein compositions for promoting wound healing and skin regeneration
     
  43. Method for stimulating wound healing
     
  44. Treatment for wounds
     
  45. Method of treating skin wounds with vectors encoding hepatocyte growth factor
     
  46. Keratinocytes useful for the treatment of wounds
     
  47. Artificial dermis and production method therefor
     
  48. Supplemented fibrin matrix delivery systems
     
  49. Growth factor delivery systems for the healing of wounds and the prevention of inflammation and disease
     
  50. Matrix for oxygen delivery to compromised tissues
     
  51. Treatment devices providing targeted antimicrobial action
     
  52. Wound and cutaneous injury healing with a nucleic acid encoding perlecan
     
  53. Topical wound dressing and method of making same
     
  54. Supplemented and unsupplemented tissue sealants, methods of their production and use
     
  55. Fibrin/fibrinogen-binding conjugate
     
  56. Protein mixtures for wound healing
     
  57. Supplemented and unsupplemented tissue sealants, methods of their production and use
     
  58. Method of promoting healing of a tympanic membrane perforation
     
  59. Storage-stable, liquid fibrinogen formulation
     
  60. Iodine preparation composition
     
  61. Material delivery system
     
  62. Enzyme-mediated modification of fibrin for tissue engineering: incorporation of proteins
     
  63. Honey based wound dressing
     
  64. Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof
     
  65. Ice dispenser for cold therapy
     
  66. Methods and compositions for enhancing fibroblast migration
     
  67. Tissue factor for influencing blood vessel formation
     
  68. Pharmaceutical compositions containing deoxyribonucleosides for wound healing
     
  69. Cultured skin and method of manufacturing the same
     
  70. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
     
  71. Combination PDGF, KGF, IGF, and IGFBP for wound healing
     
  72. Effervescent solid composition of matter
     
  73. Fibrinogen bandages and arterial bleeding models and methods of making and using thereof
     
  74. Composite dressings for the treatment of wounds
     
  75. Use of oxandrolone in the treatment of burns and other wounds
     
  76. Wound healing compositions and methods using tropoelastin and lysyl oxidase
     
  77. Antiseptic compress
     
  78. Wound treatment solution and method for using same
     
  79. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
     
  80. Regulation of wound healing by nitric oxide
     
  81. Microclysmic gel for treatment of tissue trauma and burns
     
  82. Keratinocyte cultures and uses thereof
     
  83. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
     
  84. Use of sex steroids function modulators to treat wounds and fibrotic disorders
     
  85. Use of GM-CSF to promote accelerated wound healing
     
  86. Treatment of lesions
     
  87. Hemostatic sponge based on collagen
     
  88. Thrombin derived polypeptides; compositions and methods for use
     
  89. Antioxidant enriched adhesive compositions and storage containers therefor
     
  90. Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances
     
  91. Compositions and methods for promoting wound healing
     
  92. Methods to enhance wound healing and enhanced wound coverage material
     
  93. Topical wound therapeutic compositions
     
  94. Facilitation of keloid healing with CM101/GBS toxin
     
  95. Sheets of cultured epithelial cells used for wound repair and their cryopreservation
     
  96. Stable enzymatic wound debrider
     
  97. Hemostatic agent
     
  98. Wound healing composition and method for use thereof
     
  99. Compositions and methods for wound healing
     
  100. Composition for growth hormone production and release, appetite suppression, and methods related thereto
     
  101. Fibrin microbeads prepared from fibrinogen, thrombin and factor XIII for binding cells
     
  102. Topical composition containing human epidermal growth factor
     
  103. Analysis and separation of platelet-derived growth factor proteins
     
  104. Material for activating epidermal cell multiplication
     
  105. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
     
  106. Medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction

  107. Method and compositions for promotion of wound treatment
     
  108. Cell growth accelerator and cell growth method using the same
     
  109. Wound healing and treatment of fibrotic disorders
     
  110. Methods and compositions for the treatment of wounds
     
  111. Topical pharmaceutical compositions for healing wounds
     
  112. Composition for arresting the flow of blood and method
     
  113. Skin aging and wound treatment using cell migration agents

Treatment, Yellow Fever

  1. Intranasal yellow fever vaccination

 
     
[ Outsourcing Guide ] [ Cont. Education ] [ Software/Reports ] [ Training Courses ]
[ Web Seminars ] [ Jobs ] [ Consultants ] [ Buyer's Guide ] [ Advertiser Info ]

[ Home ] [ Pharm Patents / Licensing ] [ Pharm News ] [ Federal Register ]
[ FDA Links ] [ FDA Warning Letters ] [ Pharm/Biotech Events ]
[ Newsletter Subscription ] [ Web Links ] [ Suggestions ] [ Site Map ]